Compare Stocks: ABEO, OMER, MGTX, and ORIC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.41 -1.3%	$6.40	$4.00 ▼ $7.65	$313.37M	1.33	1.30 million shs	1.60 million shs
MGTX MeiraGTx	$12.79 -0.5%	$13.20	$6.62 ▼ $15.35	$1.23B	1.27	724,249 shs	459,547 shs
OMER Omeros	$18.28 -1.7%	$14.45	$3.94 ▼ $19.65	$1.35B	2.6	1.62 million shs	1.01 million shs
ORIC Oric Pharmaceuticals	$12.04 -0.2%	$12.36	$7.23 ▼ $14.93	$1.25B	1	1.03 million shs	1.06 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-1.28%	-9.83%	-27.48%	-2.17%	-17.15%
MGTX MeiraGTx	-0.47%	-7.92%	-1.31%	+33.37%	+70.76%
OMER Omeros	-1.67%	-3.54%	+33.33%	+109.39%	+328.10%
ORIC Oric Pharmaceuticals	-0.25%	-6.38%	-12.44%	+45.59%	+14.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.41 -1.3%	$6.40	$4.00 ▼ $7.65	$313.37M	1.33	1.30 million shs	1.60 million shs
MGTX MeiraGTx	$12.79 -0.5%	$13.20	$6.62 ▼ $15.35	$1.23B	1.27	724,249 shs	459,547 shs
OMER Omeros	$18.28 -1.7%	$14.45	$3.94 ▼ $19.65	$1.35B	2.6	1.62 million shs	1.01 million shs
ORIC Oric Pharmaceuticals	$12.04 -0.2%	$12.36	$7.23 ▼ $14.93	$1.25B	1	1.03 million shs	1.06 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-1.28%	-9.83%	-27.48%	-2.17%	-17.15%
MGTX MeiraGTx	-0.47%	-7.92%	-1.31%	+33.37%	+70.76%
OMER Omeros	-1.67%	-3.54%	+33.33%	+109.39%	+328.10%
ORIC Oric Pharmaceuticals	-0.25%	-6.38%	-12.44%	+45.59%	+14.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.33	Hold	$19.33	257.36% Upside
MGTX MeiraGTx	3.00	Buy	$26.17	104.59% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	107.88% Upside
ORIC Oric Pharmaceuticals	2.79	Moderate Buy	$19.60	62.79% Upside

Current Analyst Ratings Breakdown

Latest ABEO, OMER, MGTX, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/17/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/14/2026	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00 ➝ $21.00
8/14/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $27.00
8/13/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
8/5/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/3/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
7/27/2026	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	MGTX MeiraGTx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	53.15	N/A	N/A	$2.94 per share	1.84
MGTX MeiraGTx	$81.39M	15.09	N/A	N/A	($0.07) per share	-182.71
OMER Omeros	$38.42M	34.44	$1.84 per share	9.93	($1.71) per share	-10.69
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
MGTX MeiraGTx	-$114.20M	$0.71	18.01	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	14.28	16.18	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)

Latest ABEO, OMER, MGTX, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
MGTX MeiraGTx	0.46	3.76	3.76
OMER Omeros	N/A	1.95	1.94
ORIC Oric Pharmaceuticals	N/A	13.19	13.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
MGTX MeiraGTx	67.48%
OMER Omeros	48.79%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
MGTX MeiraGTx	7.40%
OMER Omeros	10.50%
ORIC Oric Pharmaceuticals	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	57.18 million	53.12 million	Optionable
MGTX MeiraGTx	300	96.04 million	88.94 million	Optionable
OMER Omeros	210	72.39 million	64.79 million	Optionable
ORIC Oric Pharmaceuticals	80	103.65 million	97.75 million	Optionable

ABEO, OMER, MGTX, and ORIC Headlines

Recent News About These Companies

Bank of New York Mellon Corp Takes Position in Oric Pharmaceuticals, Inc. $ORIC

September 8, 2026 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC

September 4, 2026 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Moderate Buy" by Analysts

September 4, 2026 | americanbankingnews.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 4, 2026 | marketbeat.com

Braidwell LP Acquires 86,500 Shares of Oric Pharmaceuticals, Inc. $ORIC

September 3, 2026 | marketbeat.com

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake

August 31, 2026 | ad-hoc-news.deA

BlackRock Inc. Buys Shares of 6,823,973 Oric Pharmaceuticals, Inc. $ORIC

August 31, 2026 | marketbeat.com

Dominic Piscitelli Sells 77,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

August 29, 2026 | insidertrades.com

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $1,054,130.00 in Stock

August 28, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes Position in Oric Pharmaceuticals, Inc. $ORIC

August 28, 2026 | marketbeat.com

Oric Pharmaceuticals, Inc. $ORIC Shares Bought by Algert Global LLC

August 26, 2026 | marketbeat.com

Bank of America Corp DE Purchases 535,649 Shares of Oric Pharmaceuticals, Inc. $ORIC

August 22, 2026 | marketbeat.com

Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC

August 21, 2026 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month High - Here's Why

August 20, 2026 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 7, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)

August 5, 2026 | theglobeandmail.com

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

August 3, 2026 | globenewswire.com

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case

July 21, 2026 | seekingalpha.com

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

July 20, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABEO, OMER, MGTX, and ORIC Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.41 -0.07 (-1.28%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.56 +0.16 (+2.87%)

As of 09/11/2026 07:30 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

MeiraGTx NASDAQ:MGTX

$12.79 -0.06 (-0.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$13.03 +0.24 (+1.85%)

As of 09/11/2026 07:30 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Omeros NASDAQ:OMER

$18.28 -0.31 (-1.67%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$18.34 +0.06 (+0.33%)

As of 09/11/2026 07:56 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Oric Pharmaceuticals NASDAQ:ORIC

$12.04 -0.03 (-0.25%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.04 +0.01 (+0.04%)

As of 09/11/2026 07:30 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABEO, OMER, MGTX, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABEO, OMER, MGTX, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABEO, OMER, MGTX, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABEO, OMER, MGTX, and ORIC Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

MeiraGTx NASDAQ:MGTX

Omeros NASDAQ:OMER

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABEO, OMER, MGTX, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABEO, OMER, MGTX, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABEO, OMER, MGTX, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABEO, OMER, MGTX, and ORIC Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

MeiraGTx NASDAQ:MGTX

Omeros NASDAQ:OMER

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools